As of November 1, the drug containing the active substance trastuzumab derukstekan will be reimbursed, Health Minister Katherine Sójka announced on Friday (15.09.). Financial bridging will be included as early as September 18. The drug is used in patients with HER2+ breast cancer. The Health Minister also announced increased availability of preventive programs for women.
Efforts to include trastuzumab derukstekan in reimbursement had been underway for some time. Negotiations with the manufacturer have already been finalized in recent weeks, the Health Minister said. The drug is recommended for use in women with HER2+ breast cancer.
- Oncologists lik...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
